Tilray expands medical cannabis portfolio in Germany

Tilray (TLRY) Medical announced the expansion of its medical cannabis extract portfolio in Germany. Tilray’s new medical cannabis offerings in Germany includes the introduction of an additional product size for its top-selling medical cannabis extract, along with a new formulation aimed at addressing the diverse needs of patients and healthcare providers. Recognizing the increasing demand for balanced medical cannabis extracts, which are among the top-prescribed medical cannabis extracts in Germany, Tilray Medical introduces the following: Tilray THC50 CBD50: A high-potency 1:1 medical cannabis extract designed for patients requiring higher cannabinoid content, offering an option for those who need stronger therapeutic effects while maintaining the same balanced THC:CBD ratio that has become in demand in Germany. Tilray THC10 CBD10: A new trial size version of Tilray Medical’s top selling medical cannabis extract, responding to patients and physicians demand for smaller formats that allow for more accessible initial dosing and treatment exploration.